You are viewing the site in preview mode
Skip to main content
| |
No SSD (n = 473)
|
SSD (n = 224)
|
P
|
Mild (n = 46)
|
Moderate (n = 78)
|
Severe (n = 100)
|
P
|
|---|
|
Satisfaction
|
3.3 ± 1.6
|
2.5 ± 1.8
|
< 0.001
|
2.7 ± 1.8
|
2.2 ± 1.7
|
2.5 ± 1.9
|
0.344
|
|
Effect
|
3.1 ± 1.6
|
2.4 ± 1.6
|
< 0.001
|
2.6 ± 1.6
|
2.2 ± 1.5
|
2.4 ± 1.7
|
0.366
|
|
PHQ-15
|
8.0 ± 4.8
|
12.0 ± 5.5
|
< 0.001
|
12.0 ± 6.1
|
10.7 ± 5.0
|
13.1 ± 5.6
|
0.019c
|
|
WHO DAS 2.0
|
17.3 ± 5.8
|
22.7 ± 8.5
|
< 0.001
|
21.3 ± 8.0
|
21.1 ± 6.8
|
24.8 ± 9.8
|
0.006b,c
|
|
PHQ-9
|
6.8 ± 5.8
|
11.8 ± 6.8
|
< 0.001
|
10.4 ± 7.9
|
11.0 ± 6.0
|
13.4 ± 6.8
|
0.012b,c
|
|
GAD-7
|
5.1 ± 5.2
|
9.7 ± 6.1
|
< 0.001
|
7.8 ± 6.3
|
9.0 ± 5.6
|
11.1 ± 6.3
|
0.004b,c
|
|
WI-7
|
13.2 ± 5.5
|
21.4 ± 7.4
|
< 0.001
|
18.6 ± 7.3
|
20.7 ± 6.9
|
23.3 ± 7.2
|
0.001b,c
|
|
SSD-12
|
9.1 ± 9.4
|
23.6 ± 11.4
|
< 0.001
|
17.8 ± 10.8
|
22.1 ± 10.2
|
27.5 ± 10.9
|
< 0.001a,b,c
|
|
SSS-8
|
7.0 ± 5.1
|
12.0 ± 6.5
|
< 0.001
|
11.6 ± 7.0
|
10.8 ± 5.3
|
13.3 ± 7.0
|
0.034c
|
|
SF-12 (PCS)
|
45.1 ± 8.6
|
39.1 ± 9.0
|
< 0.001
|
41.0 ± 8.2
|
40.0 ± 9.0
|
37.4 ± 9.0
|
0.038b
|
|
SF-12 (MCS)
|
44.6 ± 11.5
|
34.9 ± 11.3
|
< 0.001
|
38.6 ± 13.9
|
34.4 ± 11.6
|
33.5 ± 9.8
|
0.044b
|
|
Number of visits
|
1.8 ± 0.9
|
2.2 ± 1.1
|
< 0.001
|
1.9 ± 1.0
|
1.9 ± 1.0
|
2.6 ± 1.0
|
< 0.001a,b,c
|
- Post hoc analysis was adjusted by LSD. a: P < 0.05 Mild vs. Moderate; b: P < 0.05 Mild vs. Severe; c: P < 0.05 Moderate vs. Severe
- PHQ-15: Patient Health Questionnaire 15; WHO-DAS 2.0: WHO Disability Assessment Schedule; PHQ-9: Patient Health Questionnaire 9; GAD-7: General Anxiety Disorder-7; WI-7: Whiteley-7 for health-related anxiety; SSD-12: Somatic Symptom Disorder B-criteria; SSS-8: Somatic Symptom Scale-8; SF-12: 12-item short-form health survey; PCS: physical component score; MCS: mental component score; SCID-5-RV: Structured clinical interview for DSM-5, research version
